Moazam M. Cheema
Laith A.N. Alzyood
Swati Jain
Rimon Golovey
Michele H. Mokrzycki
<p>Dr. Mokrzycki is a graduate of Boston College (B.S., 1983), and the University of Vermont College of Medicine (M.D., 1987) and received a Masters of Science in Clinical Research from the Albert Einstein College of Medicine (M.S. 2000). She completed both an Internal Medicine Residency and Clinical Nephrology Fellowship at the University of Connecticut Health Science Center in Farmington, CT. Dr Mokrzycki has been on faculty at the Albert Einstein College of Medicine since 1992, where she is a Professor of Medicine in the Division of Nephrology. She is a full time clinical nephrologist at the Montefiore Medical Center, Moses Campus.</p>
<p>Dr Mokrzycki's research interests have focused primarily on hemodialysis vascular access related complications, specifically, complications associated with tunneled catheter use such as infection/bacteremia/inflammation and dysfunction/thrombosis. </p>
<p>She is the recipient of a grant from the AETNA Foundation to study the effect of a multidisciplinary team approach to improve outcomes associated with catheter bacteremia in hemodialysis patients. </p>
<p>Dr Mokrzycki served on the Program Committee Member for the National Kidney Foundation (NKF) for 2 years, and on Faculty for the Therapeutic Apheresis Academy (TAA) for 5 years, which is held annually at the University of Virginia College of Medicine. She has been an invited speaker and/or chaired sessions at the American Society of Nephrology (ASN), National Kidney Foundation (NKF), the Vascular Access Society (VAS), Hemodialysis University (HDU), Annual Dialysis Conference (ADC), the American Society of Diagnostic and Interventional Nephrology (ASDIN), and the VEITH symposium.</p>
<p>Dr Mokrzycki served on the Catheter Endpoints Workgroup of the Kidney Health Initiative (KHI), formed by the American Society of Nephrology,the FDA and other stakeholders in End Stage Kidney Disease Innovation. Dr Mokrzycki currently serves as the Chair of the Vascular Accesss Outcomes Workgroup, a subgroup of the Nephrologists Transforming Dialysis Safety Initiative (NTDS), which is a collaboration between the American Society of Nephrology and the Centers for Disease Control. </p>
<p> </p>
<p>Dr. Mokrzycki is board certified in Nephrology and is a Fellow of the American Society of Nephrology. Clinical interests include Glomerular Diseases, Acute and Chronic Kidney Diseases, Hypertension, Kidney Stones, Renal Cystic Diseases, Dialysis, and Vascular Access for Hemodialysis.</p>
<p>Dr. Mokrzycki completed a Masters Program in Clinical Research at the Albert Einstein College of Medicine. The author of over 50 peer-reviewed publications, Dr. Mokrzycki’s research focuses on reducing hemodialysis vascular access infectious and thrombotic complications.</p>
<ol>
<li><strong>Mokrzycki MH</strong>, Yamase H, Kohn OF. Renal malacoplakia with papillary necrosis and renal failure. Am J Kidney Dis 19:587-91, 1992.</li>
<li><strong>Mokrzycki MH</strong>, Kaplan AA. Therapeutic Plasma Exchange: Complications and management. Am J Kidney Dis 23:817-27, 1994.</li>
<li><strong>Mokrzycki MH</strong>, Rickles F, Kaplan AA, Kohn OF. Thrombotic thrombocytopenic purpura in pregnancy: Successful treatment with plasma exchange. Blood Purif 13:271-82, 1995.</li>
<li>Posner L, <strong>Mokrzycki MH</strong>. Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use. Am J Nephrol 16:339-43,1996.</li>
<li>Kerr A, Spector J, <strong>Mokrzycki MH</strong>, Blau S, Simon R. V asodilator provocation of occult urinar y tract hemorrhage. J Trauma 40:152-4, 1996.</li>
<li><strong>Mokrzycki MH</strong><span style="text-decoration: underline;">,</span> Kaplan AA. Protein losses in continuous renal replacement therapies. J Am Soc Nephrol 7:1-5, 1996.</li>
<li><strong>Mokrzycki MH</strong><span style="text-decoration: underline;">,</span> Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine (d4T): Report of 5 cases. Clin Inf Dis 30:198-200, 2000.</li>
<li><strong>Mokrzycki MH</strong>, Schroppel B, von Gersdorff G, Rush H, Zdunek M, Feingold R. Tunneled cuffed catheter associated infections in hemodialysis patients seropositive for the human immunodeficiency virus. J Am Soc Nephrol 11:2122-2127, 2000.</li>
<li>Barisoni L, <strong>Mokrzycki MH</strong>, Sablay L, Nagata M, Yamase H, Mundel P. Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 58:137-143, 2000.</li>
<li>Zdunek MP, Mitra A, <strong>Mokrzycki MH</strong>. Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: Timing is important for maximizing clearance. Am J Kidney Dis 36:177-183, 2000.</li>
<li>Solomon N, <strong>Mokrzycki MH</strong>. Levofloxacin-associated allergic interstitial nephritis. Clin Nephrol 54:356, 2000.</li>
<li><strong>Mokrzycki MH</strong>, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 59:1935-1942, 2001.</li>
<li>Swiatecka-Urban A, <strong>Mokrzycki MH</strong>, Kaskel F, Da Silva F, Denamur E. Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome. Pediatr Nephrol 16:627-630, 2001.</li>
<li><strong>Mokrzycki MH,</strong> Singhal A. Cost-Effectiveness of Three Strategies of Managing Tunneled-Cuffed Hemodialysis Catheters (TCC) in Clinically Mild or Asymptomatic Bacteremias. Nephrol Dial Transpl 17(12): 2196-203, 2002.</li>
<li>Negulescu O, Coco M, Croll J, <strong>Mokrzycki MH</strong>. Large atrial thrombus formation associated with tunneled cuffed hemodialysis catheters. Clin Nephrol 59(1):40-6, 2003.</li>
<li>Golestaneh L, Laut J, Rosenberg S, Zhang M, <strong>Mokrzycki MH</strong>. Favourable outcomes in episodes of Pseudomonas bacteremia when associated with tunneled cuffed catheters (TCC) in chronic hemodialysis patients. Nephrol Dial Transplant. May;21(5):1328-33,2006.</li>
<li><strong>Mokrzycki MH</strong>, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO. Tunneled Hemodialysis Catheter Bacteremia: Risk factors for bacteremia recurrence, infectious complications and mortality. Nephrol Dial Transplant. 21(4):1024-31,2006.</li>
<li><strong>Mokrzycki MH</strong>, Zhang M, Golestaneh L, Laut J, Rosenberg SO.A randomized controlled trial comparing two management models for the treatment of tunneled cuffed catheter (TCC) bacteremia: A collaborative team model versus usual physician-managed care. Am J Kidney Dis 48(4):587-95, 2006.</li>
<li>McKenzie LM, Hendrickson, SL, Briggs WA, Dart RA, Korbet SM, <strong>Mokrzycki MH</strong>, Kimmel PL, Ahuja TS, Berns JS, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Cho M, Zhou YC, Binns-Roemer E, Kirk GD, Kopp JB, Winkler CA. NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol 18(11): 2987-95, 2007</li>
<li><strong>Mokrzycki MH.</strong> Use of prophylactic topical or intraluminal antibiotics for hemodialysis catheters. Nat Clin Pract Nephrol 4(9):478-9, 2008.</li>
<li>Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, <strong>Mokrzycki MH</strong>, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 40 (10):1175-84, 2008.</li>
<li>Sachdeva M, Bitzer M, <strong>Mokrzycki MH</strong>. Vascular access type and changes in inflammatory markers in incident dialysis patients: a pilot study. J Vascular Access 10(3):174-179, 2009.</li>
<li>Golestaneh L, Gofran A, <strong>Mokrzycki MH</strong>, Chen JL. Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing. Clin Neph 72 (4):286-291.</li>
<li>Okafor C, Ward DM, <strong>Mokrzycki MH,</strong> Weinstein R, Clark P, Balogun RA. Introduciton and overview of therapeutic apheresis. J Clin Apheresis, 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>. Advances in Hemodialysis Catheter-related Infection. U.S. Nephrol, 2010.</li>
<li><strong>Mokrzycki MH</strong>, Lok CE. Traditional and nontraditional strategies to optimize catheter function: <em>Go with more flow.</em> Kidney Int, 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>. Update 2010: Catheter-related Infection in Hemodialysis Patients. Kidney Int. 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>. Prevention and management of catheter-related infection in hemodialysis patients. Kidney Int. 2010;79(6):587-98.</li>
<li><strong>Mokrzycki MH</strong>, Balogun RA. Therapeutic Apheresis: a review of complications and recommendations for prevention and management. J Clin Apher 2011:26(5):243-8.</li>
<li>Lee T, <strong>Mokrzycki MH</strong>, Moist L, Maya I, Vazquez M, Lok CE; North American Vascular Access Consortium. Standardized definitions for hemodialysis vascular access. Semin Dial 2011;24(5):515-24.</li>
<li>Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, <strong>Mokrzycki MH</strong>, Kimmel PL, Limous S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollack M, Winkler CA. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-Associated nephropathy. J Am Soc Nephrol 2011;22(11):2129-37.</li>
<li>Sachdeva M, Hung A, Kovalchuk O, Bitzer M, <strong>Mokrzycki MH</strong>. The initial vascular access type contributes to inflammation in incident hemodialysis patients. Int J Nephrol Volume 2012; (2012) Article ID: 917465.</li>
<li>Lee T, Lok C, Vazquez M, Moist L, Maya I, <strong>Mokrzycki M</strong>. Minimizing hemodialysis catheter dysfunction: An ounce of prevention. Int J Nephrol; Volume 2012 (2012), Article ID: 170857.</li>
<li>Golestaneh L, <strong>Mokrzycki MH</strong>. Vascular Access in Therapeutic Apheresis: Update 2013. J Clin Apheresis. 2013: 28(1):64-72.</li>
<li>Nica A, Lok CE, Harris J, Lee TC, <strong>Mokrzycki MH</strong>, Maya ID, Vazquez MA, Xi W, Moist LM; From the North American Vascular Access Consortium (NAVAC). Understanding Surgical Preference and Practice in Hemodialysis Vascular Access creation. Semin Dial. 2013:26(4):520-526.</li>
<li>Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014;370 (15):1393-1401.</li>
<li><strong>Mokrzycki MH</strong>, Lok CE. Optimizing central venous catheter primary prevention trials in hemodialysis patients. Am. J.Kidney Dis. 2015;66(6):939-941.</li>
<li>Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson P, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova , Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, <strong>Mokrzycki MH</strong>, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M. Complete remission in the nephrotic syndrome study network. Clin J Am Soc Nephrol. 2016;11 (1):81-89.</li>
<li>Johns, TS, <strong>Mokrzycki MH</strong>. Optimal approach for the diagnosis of hemodialysis catheter-related bacteremia. Clin J Am Soc Nephrol 2016; 11.</li>
<li>Liang E, Rodriguez M, Mueller M, Abramowitz MK, <strong>Mokrzycki MH</strong>. Outcomes Associated with a Heparin-Free Hemodialysis Protocol and Review of the Literature. J. Clin. Nephrol. Renal Care. 2016, 2(1): 10-16.</li>
<li>Allon M, Brouwer-Maier DJ, Abreo K, Baskin KM, Bregel K, Chand D, Easom A, Mermel L, <strong>Mokrzycki MH</strong>, Patel PR, Roy-Chaudhury P, Shenoy S, Valentini RP, Wasse H. Moving Points in Nephrology: Recommended Clinical Trial Endpoints for Hemodialysis Catheters. Clin J Am Soc Nephrol. 2017</li>
<li> Golestaneh L, <strong>Mokrzycki MH</strong>. Prevention of Hemodialysis Catheters Infections: Ointments, Dressings, Locks and Catheter Hub Devices. Hemodial Int. Nov 2018</li>
<li>Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabathou S, Izmirly P, Clancy R, Belmont HM, Koenigsberg M, <strong>Mokrzycki M</strong>, Rominieki H, Graham JA, Rocca JP, Bornkamp N, Jordan N, Schulte E, Wu M, Pullman J, Slowikowski K, Raychaudhuri S, Guthridge J, James J, Buyon J, Tuschl T, Putterman C; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019 Jul;20(7):915-927</li>
<li>Fisher M, Golestaneh L, Allon M, <span style="font-family: 'Times New Roman', serif; font-size: 12pt;"> </span><span style="font-family: 'Times New Roman', serif; font-size: 12pt;">Abreo K, </span><strong style="font-family: 'Times New Roman', serif; font-size: 12pt;">Mokrzycki MH. </strong>Preventing Central Vein Catheter Associated Bloodstream Infections in Hemodialysis: Review of Current Evidence-Based Strategies and Novel Therapies. <span style="font-size: 12pt; font-family: 'Times New Roman', serif;">Clin J Am Soc Nephrol 2020;15:132-151</span></li>
<li><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Vachharajani T , Wong L, Niyyar VD, Abreo KD, <strong>Mokrzycki MH</strong>, for the Vascular Access Workgroup of the Nephrologists Transforming Dialysis Safety Initiative of the American Society of Nephrology. Buttonhole cannulation of arteriovenous fistulas in the United States. Kidney360. 2020 </span></li>
<li><strong style="text-indent: -0.25in; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-size: 12pt;">Mokrzycki MH</span></strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;"> and Coco M. Management of hemodialysis patients with suspected or confirmed COVID-19 infection: perspective of two nephrologists in the United States. Kidney360. 2020:1(4);273-278.</span></li>
<li><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">Fisher M, Yunes M, <strong>Mokrzycki MH</strong>, Golestaneh L, Alahiri E, Coco M. “Chronic Hemodialysis Patients Hospitalized with COVID-19 – Short-term Outcomes in Bronx, New York”. Kidney360 June 2020</span>1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></li>
<li><strong style="text-indent: -0.25in;"><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif;">Mokrzycki MH</span></strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">, Leigh KA, Kliger AS, Niyyar VD, Bren Asp V, Golestaneh L, Taylor Q, Novosad SA. Implementation of an Electronic Catheter Checklist in Outpatient Hemodialysis Facilities: Results of a Pilot Quality Improvement Project. Kidney360 April 2021, 2(4) 684-694</span>
<p class="MsoListParagraph" style="text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"> </p>
</li>
</ol>
<p><em><strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">Book Chapter</span></strong></em></p>
<p class="MsoListParagraph" style="text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;">Fisher M, <strong style="mso-bidi-font-weight: normal;">Mokrzycki MH.</strong> Infectious complications in vascular access. Handbook of Dialysis. Nissenson: Handbook of Dialysis Therapy, 6e.</span> <span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;">Elsevir (In press, 2021)</span></p>
<p>Michele H. Mokrzycki, MD, MS, is an attending nephrologist and Professor, Medicine at Montefiore Einstein. Dr. Mokrzycki’s clinical interests include glomerular diseases, acute and chronic kidney diseases, hypertension, kidney stones, renal cystic diseases, dialysis and vascular access for hemodialysis.</p><p>After earning her Bachelor of Science from Boston College in 1983, Dr. Morkrzycki pursued her Doctor of Medicine at University of Vermont College of Medicine, earning the degree in 1987. She performed her postdoctoral training at University of Connecticut Health Center, completing her residency in internal medicine in 1990 and her fellowship in clinical nephrology in 1992. Dr. Mokrzycki later pursued additional education, completing her Master of Science in clinical research at Einstein in 2000.</p><p>Author of over 50 peer-reviewed publications, Dr. Mokrzycki’s research focuses on reducing hemodialysis vascular access infectious and thrombotic complications. She is on the editorial board for <em>Kidney360</em>, and is an invited reviewer for several publications including the <em>Journal of the American Society of Nephrology, Hemodialysis International</em> and the <em>Journal of Vascular Access.</em></p><p>Dr. Mokrzycki is board certified in Nephrology. She is a Fellow of the American Society of Nephrology and a member of several professional societies including the National Kidney Foundation, New York Society of Nephrology and the North American Vascular Access Consortium. In 2020, she was recognized as Reviewer of the Year by <em>Kidney360</em>.</p>
Antonio Gabriel D. L. Corona
•<span style="white-space:pre;"> </span>Chronic kidney disease, acute kidney injury, glomerular diseases, electrolyte disorders and hypertension<br />•<span style="white-space:pre;"> </span>Geriatric Nephrology<br />•<span style="white-space:pre;"> </span>Palliative Nephrology<br />•<span style="white-space:pre;"> </span>Onconephrology<br />
•<span style="white-space:pre;"> </span>Palliative Nephrology and Palliative Onconephrology<br />•<span style="white-space:pre;"> </span>Medical Ethics<br />
Dr. Antonio Corona completed his Internal Medicine at GWU Providence Hospital where he also served as the Chief Resident his senior year. He went on to finish his Nephrology and Palliative Care fellowship at Baylor University Medical Center and the University of Michigan in Ann Arbor. Dr. Corona also completed Medical Bioethics training at the Gitenstein Institute for Health Law and Policy at Hofstra prior to joining Montefiore.
Jinil Yoo
<p>Dr. Jinil Yoo graduated from Seoul National University Medical School in Korea in 1967 and served in the Korean Air Force as a medical officer from 1967 to 1970. He completed a medical residency at New York Medical College-Metropolitan Hospital in 1974 and a nephrology fellowship at New York Medical College-Flower Fifth Hospital in 1976.</p>
<p>Dr. Yoo was appointed Assistant Professor of Medicine at New York Medical College in 1976 and went on to serve as Chief of Nephrology and Associate Director of Medicine at Lincoln Hospital in the Bronx from 1979 to 1988, Chief of Nephrology at Misericordia Hospital-Our Lady of Mercy Medical Center (OLM) in the Bronx from 1981 to 2008, and program Director of the Nephrology Fellowship (OLM and Lincoln Hospital) from 1981 to 1996.</p>
<p>Dr. Yoo is the Clinical Director of Nephrology at Montefiore-Wakefield Campus, a position he has held since 2008. He is also the Medical Director of Bronx River Nephrocare and its affiliated Dialysis Center at Jewish Home and Hospital in Bronx, a position he has held since 1998.</p>
<p>Dr. Yoo is board certified in internal medicine and nephrology and has served as a member of the Board of Trustees at Nyack College & Alliance Theological Seminary from 1995 to 2001, as a board member at the Office of Professional Medical Conduct of the New York State Department of Health from 2002 to 2009. Dr. Yoo has appeared multiple times on the list of “Best Doctors” by New York Magazine; “America’s Top Physicians” by Consumers’ Research Council of America; “New York Super Doctors” by Key Professional Media; and “Top Doctors of New York Metro Area” by Castle-Connolly Guide.</p>
<p>Dr. Yoo graduated from Seoul National University-Medical School in Korea 1967 and served in the Korean Air-Force as a Medical Officer 1967-1970. He completed his Medical Residency at NY Med College-Metropolitan Hospital in 1974 and his Nephrology Fellowship at NY Med College-Flower Fifth Hospital in 1976.</p><p>Dr. Yoo was appointed as Assistant Professor of Medicine at NY Med College in 1976 and would go on to serve as the chief of Nephrology and Associate Director of Medicine at Lincoln Hospital in the Bronx from 1979-1988; Chief of Nephrology at Misericordia Hospital to Our Lady of Mercy Medical Center (OLM) in the Bronx from 1981-2008; and Program Director of Nephrology Fellowship (OLM and Lincoln Hospital) from 1981-1996.</p><p>Dr. Yoo is the Clinical Director of Nephrology at Montefiore-Wakefield Campus, a position he has held since 2008. He is also the Medical Director of Bronx River Nephrocare and its affiliated Dialysis Center at Jewish Home and Hospital in Bronx, a position he has held on to since 1998.</p><p>He is Board-certified in Internal Medicine and Nephrology and has served as a Member of the Board of Trustees at Nyack College & Alliance Theological Seminary from 1995-2001; and as Board Member at OPMC of NY State Dept. of Health from 2002-2009. Dr. Yoo has appeared multiple times on the list of “Best Doctors” by New York Magazine; “America’s Top Physicians” by Consumers’ Research Council of America; “New York Super Doctors” by Key Professional Media; and “Top Doctors of New York Metro Area” by Castle-Connolly Guide.</p>
Deep Sharma
Kidney stones, Glomerular diseases, Chronic kidney disease, End Stage renal disease
Treatment for anemia in patients with chronic kidney disease and end stage renal disease on dialysis
<p></p>Deep Sharma, MBBS, earned his medical degree from University College of Medical Sciences in Delhi, India. He then completed his residency and chief residency at Good Samaritan Hospital, Baltimore followed by his nephrology fellowship at Montefiore Medical Center where he joined as faculty after completion of his fellowship. He is board certified in Medicine and Nephrology and is a member of the American Society of Nephrology. Dr. Sharma is the clinical director of Nephrology for Weiler Hospital and the medical director of Fresenius Eastchester and Fresenius Freedom Center of the Bronx that treats patients who need dialysis for End Stage Kidney disease, both incenter and at home. With the help of his Urology colleagues, he helped establish the kidney stone program at Montefiore and that sees patients with kidneys stones in the clinic. Dr. Sharma has been involved in clinical studies looking at muscle mass in patients with kidney disease and the treatment of anemia in patients with chronic kidney disease and dialysis.<p></p>
Robin O. Russell
<p class="MsoNormal">Dr. Robin O. Russell obtained his M.D. from the University of New Mexico. He would complete his Medicine Residency and Nephrology Fellowship at Harlem Hospital Center in New York. He would go on to serve as a nephrology attending at Lincoln and Misericordia Hospitals, before a lengthy stint as Medical Director of Hemodialysis at Terrance Cardinal Cooke Health Care Center from 1992 to 2010. Since 1990, he had been increasingly active in the Geriatric Medicine Teaching Program at Our Lady of Mercy Medical Center, now the Wakefield Campus of Montefiore Medical Center.</p><p class="MsoNormal">Dr. Russell's major interests have been inpatient, outpatient and long-term care geriatric medicine, all in the setting of a large geriatric medicine fellowship program. He continues to have a special interest in renal disease in the geriatric population.</p><p class="MsoNormal"> </p>